| Literature DB >> 20498832 |
Martina Lari1, Ermanno Rizzi, Lucio Milani, Giorgio Corti, Carlotta Balsamo, Stefania Vai, Giulio Catalano, Elena Pilli, Laura Longo, Silvana Condemi, Paolo Giunti, Catherine Hänni, Gianluca De Bellis, Ludovic Orlando, Guido Barbujani, David Caramelli.
Abstract
BACKGROUND: The high frequency (around 0.70 worldwide) and the relatively young age (between 14,000 and 62,000 years) of a derived group of haplotypes, haplogroup D, at the microcephalin (MCPH1) locus led to the proposal that haplogroup D originated in a human lineage that separated from modern humans >1 million years ago, evolved under strong positive selection, and passed into the human gene pool by an episode of admixture circa 37,000 years ago. The geographic distribution of haplogroup D, with marked differences between Africa and Eurasia, suggested that the archaic human form admixing with anatomically modern humans might have been Neanderthal. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2010 PMID: 20498832 PMCID: PMC2871044 DOI: 10.1371/journal.pone.0010648
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Sequencing results for the amplifications of mtDNA fragments on MLS Neanderthal sample.
| LOCUS | PCR | CLONES | 454 FLX | |||
| mtDNA | Ne | MH | Ne | MH | Ne% | |
| 16,109–16,191 | 1 | 20 | 0 | - | - | 100 |
| 2 | 18 | 2 | - | - | 90 | |
| 3 | 20 | 0 | 100 | |||
| 16,220–16,282 | 1 | 17 | 3 | - | - | 85 |
| 2 | 16 | 4 | - | - | 80 | |
| 3 | 15 | 5 | 75 | |||
| 6,267 | 1 | no ampl. | no ampl. | - | - | |
| 2 | 17 | 3 | - | - | 85 | |
| 3 | 19 | 1 | 95 | |||
| 88,75 | ||||||
‘CLONES’ means results from cloning and Sanger sequencing. ‘454 FLX’ means results from Roche/454 Life Science technology. (Ne) Neanderthal; (MH) Modern Human; (no ampl.) no amplification product obtained; (-) sequencing not attempted.
Sequencing results for the amplifications of nuclear loci on MLS Neanderthal sample.
| LOCUS | PCR | CLONES | 454 FLX | |||
| nDNA | ancestral | derived | ancestral | derived | ancestral % | |
| LCT (MCM6) -13910 | 1 | 30 | 0 | - | - | 100 |
| 2 | 30 | 0 | - | - | 100 | |
| 3 | no ampl. | no ampl. | - | - | - | |
| 4 | - | - | 45101 | 19 | 99.96 | |
| MCPH1 37995 | 1 | 40 | 0 | - | - | 100 |
| 2 | no ampl. | no ampl. | - | - | - | |
| 3 | 35 | 0 | - | - | 100 | |
| 4 | 40 | 0 | - | - | 100 | |
| 5 | 38 | 0 | - | - | 100 | |
| 6 | no ampl. | no ampl. | - | - | - | |
| 7 | no ampl. | no ampl. | - | - | - | |
| 8 | - | - | 12494 | 189 | 98.51 | |
‘CLONES’ means results from cloning and Sanger sequencing. ‘454 FLX’ means results from Roche/454 Life Science technology. (no ampl.) no amplification product obtained; (-) sequencing not attempted.